Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Fig. 4

Year 1 effect of IFN β-1a 44 μg SC tiw in prespecified subgroups of patients. a ORs of IFN β-1a 44 μg SC tiw compared with placebo for the proportion of patients free from relapse at Year 1. Based on logistic model adjusting for age, number of pre-study relapses, baseline EDSS score, and baseline BOD as covariates. (Age, number of pre-study relapses, baseline EDSS score, and baseline BOD were not covariates used in analysis of the subgroups determined by each of these respective characteristics.) b Rate ratios for placebo compared with IFN β-1a 44 μg SC tiw for the number of active T2 lesions up to Year 1. Based on a negative binomial model adjusting for baseline BOD as covariate, and log number of scans up to Year 1 as an offset variable. Baseline BOD was not a covariate used in the analysis of the baseline BOD subgroups. Active T2 lesions up to 1 year included those lesions detected at the 6-month or 1-year MRI assessments. aMedian baseline EDSS score: 2.5. bMedian baseline BOD: 1992.5 mm2. BOD: burden of disease; CI: confidence interval; EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; MRI: magnetic resonance imaging; MS: multiple sclerosis; OR: odds ratio; SC: subcutaneously; tiw: three times weekly

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us